Skip to content

Study · In vitro (cells) · 2019

9 results

MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway.

Che N, Qiu W, Wang JK, Sun XX, Xu LX, Liu R, Gu L

European review for medical and pharmacological sciences1 Apr 2019Cited by 20 (Europe PMC)

PMID31081069 (opens in a new tab)DOI10.26355/eurrev_201904_17676 (opens in a new tab)PepBankPUB-31081069
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In hFOB1.19 osteoblast cells, MOTS‑c 1.0 µM for 24 h significantly increased cell viability.

    In plain wordsIn bone-forming cells, MOTS‑c increased cell viability.

    Peptide
    MOTS-c
    Outcome
    IncreaseCell viability at 1.0 µM for 24 h
    Study

    n: not reported in source

    hFOB1.19 osteoblast cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1.0 µM · 24 hAs given in this study.

    Source sentences

    Summary
    Cell viability was significantly increased after treatment of 1.0 μM MOTS-c for 24 h or 0.5 μM MOTS-c for 48 h in a time-dependent manner.
    1 context sentence
    Summary · context
    Viability of hFOB1.19 cells treated with MOTS-c was detected by CCK-8 assay.
  2. 02LabIn vitro (cells)Efficacy outcome

    In hFOB1.19 osteoblast cells, MOTS‑c 0.5 µM for 48 h significantly increased cell viability.

    In plain wordsIn bone-forming cells, MOTS‑c increased cell viability.

    Peptide
    MOTS-c
    Outcome
    IncreaseCell viability at 0.5 µM for 48 h
    Study

    n: not reported in source

    hFOB1.19 osteoblast cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 µM · 48 hAs given in this study.

    Source sentences

    Summary
    Cell viability was significantly increased after treatment of 1.0 μM MOTS-c for 24 h or 0.5 μM MOTS-c for 48 h in a time-dependent manner.
    1 context sentence
    Summary · context
    Viability of hFOB1.19 cells treated with MOTS-c was detected by CCK-8 assay.
  3. 03LabIn vitro (cells)Mechanism

    In hFOB1.19 osteoblast cells, TGF-β mRNA and protein expression depended on the MOTS‑c concentration; the direction is not stated.

    In plain wordsIn bone-forming cells, the amount of TGF-β changed with the MOTS‑c concentration.

    Peptide
    MOTS-c
    Outcome
    Direction not reportedTGF-β mRNA and protein expression
    Study

    n: not reported in source

    hFOB1.19 osteoblast cells
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mRNA and protein expressions of TGF-β, SMAD7, COL1A1 and COL1A2 in hFOB1.19 cells were dependent on the concentration of MOTS-c.
    1 context sentence
    Summary · context
    Viability of hFOB1.19 cells treated with MOTS-c was detected by CCK-8 assay.
  4. 04LabIn vitro (cells)Mechanism

    In hFOB1.19 osteoblast cells, SMAD7 mRNA and protein expression depended on the MOTS‑c concentration; the direction is not stated.

    In plain wordsIn bone-forming cells, the amount of SMAD7 changed with the MOTS‑c concentration.

    Peptide
    MOTS-c
    Outcome
    Direction not reportedSMAD7 mRNA and protein expression
    Study

    n: not reported in source

    hFOB1.19 osteoblast cells
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mRNA and protein expressions of TGF-β, SMAD7, COL1A1 and COL1A2 in hFOB1.19 cells were dependent on the concentration of MOTS-c.
    1 context sentence
    Summary · context
    Viability of hFOB1.19 cells treated with MOTS-c was detected by CCK-8 assay.
  5. 05LabIn vitro (cells)Mechanism

    In hFOB1.19 osteoblast cells, COL1A1 mRNA and protein expression depended on the MOTS‑c concentration; the direction is not stated.

    In plain wordsIn bone-forming cells, the amount of the collagen gene COL1A1 changed with the MOTS‑c concentration.

    Peptide
    MOTS-c
    Outcome
    Direction not reportedCOL1A1 mRNA and protein expression by concentration
    Study

    n: not reported in source

    hFOB1.19 osteoblast cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mRNA and protein expressions of TGF-β, SMAD7, COL1A1 and COL1A2 in hFOB1.19 cells were dependent on the concentration of MOTS-c.
    1 context sentence
    Summary · context
    Viability of hFOB1.19 cells treated with MOTS-c was detected by CCK-8 assay.
  6. 06LabIn vitro (cells)Mechanism

    In hFOB1.19 osteoblast cells, COL1A2 mRNA and protein expression depended on the MOTS‑c concentration; the direction is not stated.

    In plain wordsIn bone-forming cells, the amount of the collagen gene COL1A2 changed with the MOTS‑c concentration.

    Peptide
    MOTS-c
    Outcome
    Direction not reportedCOL1A2 mRNA and protein expression by concentration
    Study

    n: not reported in source

    hFOB1.19 osteoblast cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mRNA and protein expressions of TGF-β, SMAD7, COL1A1 and COL1A2 in hFOB1.19 cells were dependent on the concentration of MOTS-c.
    1 context sentence
    Summary · context
    Viability of hFOB1.19 cells treated with MOTS-c was detected by CCK-8 assay.
  7. 07LabIn vitro (cells)Efficacy outcome

    In hFOB1.19 osteoblast cells, MOTS‑c increased COL1A1 expression.

    In plain wordsIn bone-forming cells, MOTS‑c increased the activity of the collagen gene COL1A1.

    Peptide
    MOTS-c
    Outcome
    IncreaseCOL1A1 expression
    Study

    n: not reported in source

    hFOB1.19 osteoblast cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c increased the expressions of COL1A1 and COL1A2, which were partially reversed by knockdown of TGF-β or SMAD7.
    1 context sentence
    Summary · context
    Viability of hFOB1.19 cells treated with MOTS-c was detected by CCK-8 assay.
  8. 08LabIn vitro (cells)Efficacy outcome

    In hFOB1.19 osteoblast cells, MOTS‑c increased COL1A2 expression.

    In plain wordsIn bone-forming cells, MOTS‑c increased the activity of the collagen gene COL1A2.

    Peptide
    MOTS-c
    Outcome
    IncreaseCOL1A2 expression
    Study

    n: not reported in source

    hFOB1.19 osteoblast cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c increased the expressions of COL1A1 and COL1A2, which were partially reversed by knockdown of TGF-β or SMAD7.
    1 context sentence
    Summary · context
    Viability of hFOB1.19 cells treated with MOTS-c was detected by CCK-8 assay.
  9. 09LabIn vitro (cells)Mechanism

    In hFOB1.19 osteoblast cells, knockdown of TGF-β or SMAD7 partially reversed the MOTS‑c induced increase in COL1A1 and COL1A2 expression.

    In plain wordsIn bone-forming cells, switching off TGF-β or SMAD7 partly cancelled the MOTS‑c boost to collagen genes.

    Peptide
    MOTS-c
    Outcome
    Not applicableMOTS-c effect on COL1A1 and COL1A2 with TGF-β or SMAD7 knockdown
    Study

    n: not reported in source

    hFOB1.19 osteoblast cells
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, MOTS-c increased the expressions of COL1A1 and COL1A2, which were partially reversed by knockdown of TGF-β or SMAD7.
    1 context sentence
    Summary · context
    Viability of hFOB1.19 cells treated with MOTS-c was detected by CCK-8 assay.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.